APTX News and Press, Aptinyx Inc. From 09/14/23

Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...

DocuSign Inc. (DOCU) is expected to report $0.11 for Q2 2024 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Concrete Pumping Holdings Inc. (BBCP) is expected to report $0.16 for Q3 2023 ...

Aptinyx Inc. (APTX) is expected to report $-0.05 for Q2 2023

Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, Aptinyx completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AMC Entertainment (NYSE: AMC ) stock is in the news after the movie theater company announced it will launch its own line of popcorn at Walmart (NYSE: WMT ). The new line of AMC Entertainment popcorn will start ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Supavadee butradee / Shutterstock.com AdaptHealth (NASDAQ: AHCO ) stock is falling on Tuesday following the release of the company’s earnings report for the fourth quarter of 2022. The bad news for ...

Clinical-stage biotech Aptinyx Inc ( NASDAQ: APTX ) lost ~54% pre-market Tuesday after announcing a setback for its Phase 2 trial for NYX-458 in patients with cognitive impairment linked to Parkinson’s disease and dementia with Lewy bodies. The company said that regarding t...

NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company will terminate its ongoing study of NYX-783 in PTSD and analyze th...

Summary Aptinyx is a clinical-stage biotech company with two drug candidates, NYX-458 and NYX-783 aiming to modulate NMDA receptors. A Phase 2 topline data readout of NYX-458 in Parkinson’s disease dementia is announced for the coming days or weeks. Aptinyx’s stock has...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SV...